Core Viewpoint - The article emphasizes the urgent need for a national strategy to address obesity in China, highlighting the launch of a three-year "Weight Management Year" initiative aimed at promoting healthy lifestyles and controlling chronic diseases [3][6]. Group 1: Obesity as a National Health Issue - Obesity has become a significant burden on the national healthcare system, with medical expenses related to obesity-related diseases reaching 200 billion yuan annually, averaging about 700 million yuan per day [5]. - By 2030, it is projected that 70% of the population will be overweight or obese, with the number of overweight and obese adults reaching 627 million by 2050 [4]. - The rising obesity rates are linked to lifestyle changes, including increased consumption of high-calorie foods and decreased physical activity [6]. Group 2: Health Implications of Obesity - Obesity is a major driver of chronic diseases in China, contributing to conditions such as hypertension, diabetes, and cardiovascular diseases [5]. - In 2019, deaths from cardiovascular diseases due to high body mass index (BMI) accounted for 11.98% of total deaths, with approximately 549,500 fatalities [5]. - The prevalence of diabetes in China has reached 116.4 million, making it the highest globally, with obesity being a key factor in insulin resistance [5]. Group 3: Economic Impact and Future Projections - If effective weight management is achieved, it is estimated that the economic losses due to obesity could be reduced by hundreds of billions of yuan annually [6]. - The proportion of healthcare spending related to weight management is expected to rise from 8% in 2022 to 22% by 2030, indicating a growing financial burden on the healthcare system [5]. Group 4: Call to Action - The initiative requires collaboration among the government, society, healthcare institutions, and individuals to promote healthy living and effective weight management [7]. - The government is urged to enhance policy guidance, promote health awareness, and improve public sports facilities to encourage physical activity [7]. - Individuals are encouraged to adopt healthy eating habits and engage in regular exercise as part of the national effort to manage weight [7].

整理 | GLP1减重宝典内容团队 2025年5月11日，礼来公司公布了SURMOUNT-5研究的详细结果。该研究是一项3b期开放标签临床试验，旨在评估GIP/GLP-1受体激动 剂双药替尔泊肽与GLP-1受体激动剂司美格鲁肽在患有肥胖症或至少一种合并症（例如高血压、血脂异常、阻塞性睡眠呼吸暂停或心血 管疾病）但无糖尿病的超重成年人中的疗效和安全性。 研究显示， 替尔泊肽在所有关键的减重和腰围减少终点方面均优于司美格鲁肽。 在72周的研究中，替尔泊肽平均减重20.2%，而司美格 鲁肽平均减重13.7%。完整结果已在第32届欧洲肥胖大会上公布，并同时发表在《新英格兰医学杂志》上。 在研究的主要终点方面，替尔泊肽的相对减重效果是司美格鲁肽的1.47倍。 数据显示，在第72周，替尔泊肽平均减重20.2%，而司美格 鲁肽平均减重13.7%。替尔泊肽组参与者平均减重22.8公斤，而司美格鲁肽组参与者平均减重15.0公斤。 在关键次要终点方面，替尔泊肽在所有减重指标上均优于司美格鲁肽。替尔泊肽组有64.6%的参与者减重至少15%，而司美格鲁肽组仅 为40.1%。此外，替尔泊肽组平均腰围减少18.4厘米，司美格鲁肽组为13 ...

Core Viewpoint - The article discusses the weight loss journey of Yang Tianzhen, highlighting her recent physical transformation and the methods she employed, including exercise and dietary changes, while clarifying that her weight loss is not solely due to traditional dieting methods [4][8]. Group 1: Yang Tianzhen's Weight Loss Journey - Yang Tianzhen has recently shared her weight loss progress, showcasing her commitment to exercise, particularly badminton, which has resulted in visible muscle definition [2][7]. - Despite public admiration for her efforts, there are mixed reactions, with some questioning the authenticity of her weight loss and others noting her previous statements against dieting [4]. - Yang underwent gastric surgery five years ago to manage diabetes, emphasizing that her primary motivation for the surgery was health-related rather than weight loss [4][5]. Group 2: Celebrity Weight Loss Trends - The article notes a surge in weight loss stories among celebrities, with many utilizing medications like Semaglutide and Tirzepatide for weight management [9]. - Elon Musk reported a weight loss of 30 pounds (approximately 27.2 kg) using Semaglutide [9]. - Other celebrities, including Whoopi Goldberg and Kelly Clarkson, have also shared their experiences with weight loss medications, highlighting significant weight reductions [11][13]. Group 3: Efficacy of Semaglutide - Clinical trials (STEP series) indicate that Semaglutide can lead to an average weight loss of 15% to 18% in obese patients, significantly outperforming placebo groups [21][26]. - In the STEP 1 trial, participants lost an average of 14.9% of their body weight, with over one-third losing more than 20% [23]. - The FDA approved Semaglutide for long-term weight management in adults with obesity or overweight conditions in June 2021, marking it as a significant advancement in obesity treatment [26]. Group 4: Efficacy of Tirzepatide - The SURMOUNT studies demonstrate that Tirzepatide can achieve substantial weight loss, with participants losing up to 26.6% of their body weight over 72 weeks [31]. - In the SURMOUNT-2 trial, patients with type 2 diabetes lost an average of 15.7% of their body weight, showcasing the drug's effectiveness [29]. - The FDA approved Tirzepatide for obesity treatment based on its promising results in clinical trials [30].

面对我国成年人超重率达3 4.3%、肥胖率1 6.4%的严峻形势（数据来源：《中国居民营养与慢性病状况报告》），首都率先打出防控 组合拳。市疾控系统联动1 6部门组建专项工作组，依托"科普传播-环境改造-能力建设"三维体系，重点突破职场人群代谢综合征、青 少年肥胖率攀升等八大痛点。 ▍加强科学普及和倡导 1.编制权威知识读本： 根据体重管理相关专业知识，编撰《首都居民体重管理核心指南》，系统整合能量平衡原理、科学运动方案及心理调适方法等专业知 识模块。 2.制作体重管理工具包： 国家卫健委联合16部委发起的"健康体重管理年"专项行动在京正式落地！北京市疾控中心今日发布《健康体重管理三年行动方案》， 通过六大战略维度、25项创新措施，构建覆盖2100万常住人口的体重健康防护网。这项系统工程预计将降低肥胖相关慢性病发病率 12%，每年减少社会经济损失逾8亿元。 开发制作微图文、短视频和老年人健康体重管理等工具包，多种渠道推广。 3.权威平台设立专栏： 在中心"两微两刊"权威平台（北京市疾控中心微信公众号、北京市疾控中心微博；《健康》、《健康少年画报》）设立体重管理专 栏。 4.推广体重管理经验做法： 向全市医疗卫 ...

整理 | GLP1减重宝典内容团队 近日，武汉邮局海关在监管进境邮件时，发现1个申报为"化妆品"的邮件过机图像异常。经人工开箱查验，发现不同颜色、不同形状，仅用透明 塑料袋简单包装的彩色药品300包、1800粒，重720克。 经现场快速检测，发现药片甲基安非他明呈阳性。甲基安非他明是冰毒的有效成分，被列为第一类精神药品，具有成瘾性。长期服用含有管制 类精神药物成分的产品会产生药物依赖，严重危害身心健康。目前，海关已依法予以暂扣。 加入专家库与我们深度讨论 「GLP-1俱乐部」覆盖数百位专业人士，构建了围绕GLP-1产业链上下游、覆盖多个板块的专家库，成为了业内顶尖专业人士获取行业真知灼见的首要选择。加入 专家库请添加下方「运营负责人」微信，并提供名片和必要的个人信息。 ▂▂▂▂▂ 与 3W+粉丝 和 数百位专家 一起 参与GLP-1的减重降糖革命 *本文仅供医疗卫生专业人士参考 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添 ...

整理 | GLP1减重宝典内容团队 1741 G t 5 5 50 ] 我们人体内奔涌着一条能量长河 . I & Balla IL I-L 当能量长河矢控 过度储存的脂肪泛滥 糖尿病 高血压 冠山病 sim Há 脂肪 ins wo DV22 肥胖就如同洪水 侵害人们的健康 e O 在中国， 约50%的成年人存在超重或肥胖 而其中高达81.8%的肥胖人群有合并脂肪肝 我国肥胖人群与合并脂肪肝人群化重 正常人群必重 肥胖人群必重 合并脂肪肝人群VV 50% 50% I8 2% 81.8% 肥胖人群式并状图 肝脏作为人体的代谢中枢,一旦被脂肪"淹没" 便可能引发一系列的严重健康问题 膀岛索扣抗 → 心血管疾病 w晨営常 动脉粥样硬化 血糖升高 > SV 血管内皮 I力能障碍 四压升温 > 脂肪肝 脂肪肝 健康肝脏 脂肪性肝炎 肝硬化 脂肪胜肝纤纤维化 -治水困局 亟需突破- 传统的减重干预手段 难解肥胖困局 o BLOS o 2 G 0 an @ o ge o 0 0 o 0 四千年前，大禹"疏堵结合"治理洪水的智慧 为现代医学破解肥胖困局提供了启示 单纯靠生活方式干预：控制饮食、增加运动 患者依从性低，难以扭转 ...

Core Viewpoint - China has the highest number of overweight and obese individuals globally, with over half of the adult population affected, leading to significant health concerns and potential market opportunities for weight loss solutions [1][2]. Group 1: Obesity Statistics - As of 2021, 16.4% of adults in China are classified as obese, while 34.3% are overweight, totaling approximately 532 million individuals, with nearly 100 million being obese [1]. - A 2020 study predicts that by 2030, the number of overweight adults in China will reach 540 million, and the obese population will increase to 150 million, representing growth of 2.8 times and 7.5 times, respectively, since 2000 [1]. Group 2: Medication Usage and Compliance - Semaglutide, a GLP-1 receptor agonist, has transformed the weight loss market, but many users discontinue its use after a period [2]. - Research indicates that 44% of patients remain on semaglutide after three months, 33% after six months, and only 19% after one year. In contrast, 63%, 56%, and 40% of semaglutide users continue after three months, six months, and one year, respectively [4]. Group 3: Effects of Discontinuation - A clinical trial showed that participants lost an average of 10.6% of their body weight during 20 weeks of semaglutide treatment, but those who switched to a placebo regained an average of 6.9% of their weight, while those who continued with semaglutide lost an additional 7.9% [5]. - An observational study found that 18% of patients regained their lost weight after one year off semaglutide, with 26% regaining more than 25% of their lost weight, while 56% maintained or continued to lose weight [5]. Group 4: Reasons for Discontinuation - Common side effects of GLP-1RA drugs include nausea, diarrhea, and vomiting, which may lead to discontinuation. Even at low doses, 17% of patients reported nausea, with higher rates of gastrointestinal issues at increased doses [6]. - Supply issues have also contributed to discontinuation, as semaglutide has been in short supply since 2022 [7]. - Other reasons for stopping include reaching a weight loss plateau or achieving target weight [9][10]. Group 5: Recommendations for Discontinuation - Gradual dose reduction is recommended to minimize rebound hunger and maintain weight loss. Patients should monitor their appetite and weight closely after discontinuation [11][14]. - Maintaining a healthy lifestyle post-medication is crucial to prevent weight regain, as obesity is a chronic condition requiring ongoing management [22]. Group 6: Lifestyle Management - The latest Chinese weight loss guidelines emphasize lifestyle interventions, including dietary management, exercise, and behavioral changes, as essential for long-term weight management [15]. - Dietary management aims to reduce caloric intake while improving metabolic health, with various dietary patterns showing short-term weight loss effects [16][18]. - Exercise plays a significant role in maintaining weight loss and improving quality of life, despite only achieving modest weight reductions on its own [19]. - Behavioral management is critical for successful weight loss, with structured programs showing significant weight reduction in the initial months [20][21].

国家卫生健康委携手教育部、体育总局、国家中医药局等16个部委重磅推出"体重管理年"全民健康促进活动。这项为期3年的专项行动将通过多 维度健康干预，全面提升国民体重管理能力，推动建立科学健康的生活方式。 在2025年3月9日举行的十四届全国人大三次会议记者会上，国家卫生健康委员会主任雷海潮特别强调，该计划将重点聚焦两大核心任务：一是 系统化普及健康生活理念，二是强化慢性病综合防控体系。通过政府主导、多部门协作、全社会参与的模式，切实改善我国居民体重异常问 题。 这项创新性的健康促进工程将整合科普宣传、技能培训、行为干预等多种手段，旨在让健康体重管理理念深入人心，最终实现全民健康素养的 整体提升。 结合地域饮食文化差异，推出全国七大地区的四季减重食谱，从BMI标准到个性化能量计算，全面指导科学减重。以下是核心要点整理： ▍超重肥胖的判定标准 BMI = 体重(kg) ÷ 身高(m)的平方 ▍依照地域制定科学食谱 想吃得健康又美味？这份分地域定制的科学饮食方案请收好！ 四大区域特色食谱 【健康对照表】 ✓ 标准身材：18.5-24 ✓ 超重预警：24-28 ✓ 肥胖分级：28以上（分轻度、中度、重度和极重度） 东北 ...

Core Insights - Oral GLP-1 weight loss drugs are expected to become a significant product cycle in the biopharmaceutical sector, with market shares projected to reach 24% and 32% by 2030 and 2035, respectively, resulting in market sizes of $22.3 billion and $38.1 billion [2] Group 1: Market Dynamics - Goldman Sachs has removed Pfizer's danuglipron from its weight loss drug market model, previously forecasting sales of $1.2 billion and $1.9 billion for 2030 and 2035 [2] - The market share forecast for Eli Lilly's orforglipron has been increased, with expectations that it will capture half of the market share left by Pfizer, while the other half will be distributed among other oral products [2] - Adjusted risk-adjusted sales forecasts for orforglipron are now $1 billion in 2026, $17.2 billion in 2030, and $24.5 billion in 2035, up from previous estimates of $1 billion, $16.5 billion, and $23.5 billion, respectively [2] Group 2: Competitive Landscape - Goldman Sachs maintains its sales forecast for Novo Nordisk's oral semaglutide at $5.3 billion, indicating that despite orforglipron's anticipated market advantage, there remains market space for oral semaglutide 25mg due to low likelihood of generic drug entry and extended price protection until orforglipron's patent expiration [4] Group 3: Patient Preferences and Pricing - The obesity market is being segmented by BMI and treatment type (oral vs. injectable), with oral medications likely to attract more patients; approximately 50% of patients may prefer oral medications despite lower efficacy compared to injectables [5] - Initial monthly net prices for the first oral drugs (Eli Lilly's orforglipron and Novo Nordisk's oral semaglutide 25mg) are expected to be around $650, decreasing to $457 and $308 by 2030 and 2035, respectively, approaching the pricing of injectable drugs [5]

整理 | GLP1减重宝典内容团队 5月11日是"世界防治肥胖日"。近30年来，我国肥胖与超重人群迅速增长，已成为威胁居民健康的重大公共卫生问题。 肥胖不仅是独立 的疾病，也是多种慢性病的重要诱因 ，若不能有效控制，将持续推高相关慢病的发生率。 肥胖问题早已突破个人层面，演变为全球范围的代谢性挑战。世界卫生组织数据显示，2020年全球超重或肥胖人口已超20亿，预计到 2035年将增至33亿。截至2021年，中国25岁以上人群中，超重和肥胖者多达4.02亿，位居全球首位。根据预测， 到2030年，我国成人 和儿童的超重与肥胖率将分别达到70.5%和31.8%，肥胖已成为我国第六大致死致残危险因素。 为应对这一挑战， 国家卫健委于2024年6月联合16个部门共同启动"体重管理年"， 旨在提升公众健康意识，普及科学体重管理理念，从 政策层面强化控肥行动，这也是"健康中国"战略的重要组成部分。 在全球范围内，防控肥胖的措施也正持续推进。《柳叶刀·糖尿病与内分泌学》近日发布一份重要报告，建议在诊断肥胖时将体脂指标 （如腰围、腰臀比、腰高比或体脂含量）与体质指数（BMI）结合使用，以降低误判风险。这一新型诊断方法不仅提升 ...